聚乙二醇化干扰素α-2a时代原发性血小板增多症女性的妊娠结局：卡塔尔的经验
Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar.
作者信息
Abu-Tineh Mohammad, Kassem Nancy, Abdulla Mohammad Abdul-Jaber, Ismail Omar Mohammad, Ghasoub Rola, Aldapt Mahmood B, Yassin Mohamed A
机构信息
Department of Medical Education, Hamad Medical Corporation (HMC), Doha, Qatar.
National Center for Cancer Care and Research, Department of Pharmacy, HMC, Doha, Qatar.
出版信息
Case Rep Oncol. 2020 Mar 26;13(1):336-340. doi: 10.1159/000506447. eCollection 2020 Jan-Apr.
Abstract
Myeloproliferative neoplasms are a diversified group of diseases of the hematopoietic stem cell, such as essential thrombocythemia (ET) and polycythemia vera. They are mainly caused by mutations in the following genes: and . All carry an increased risk to transform into acute leukemia or chronic myelogenous leukemia along with thrombosis and hemorrhagic complications. Treatment of such disorders during pregnancy is a challenging footstep, given the high risk of complications for both the mother and the fetus. Here, we report about two pregnant females with ET that has been treated with pegylated interferon alpha with safe and effective outcome.
摘要
骨髓增殖性肿瘤是造血干细胞的一组多样化疾病，如原发性血小板增多症（ET）和真性红细胞增多症。它们主要由以下基因的突变引起： 和 。所有这些疾病都有转化为急性白血病或慢性粒细胞白血病的风险增加，同时伴有血栓形成和出血并发症。鉴于对母亲和胎儿都有很高的并发症风险，孕期治疗此类疾病是具有挑战性的一步。在此，我们报告两例患有ET的孕妇，她们接受了聚乙二醇化干扰素α治疗，结果安全有效。
相似文献
1
Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar.聚乙二醇化干扰素α-2a时代原发性血小板增多症女性的妊娠结局：卡塔尔的经验
Case Rep Oncol. 2020 Mar 26;13(1):336-340. doi: 10.1159/000506447. eCollection 2020 Jan-Apr.
2
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.真性红细胞增多症和原发性血小板增多症：2017 年诊断、危险分层和治疗更新。
Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607.
3
JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.哥伦比亚BCR-ABL阴性骨髓增殖性肿瘤患者的JAK2、CALR和MPL突变谱
Colomb Med (Cali). 2023 Sep 30;54(3):e2035353. doi: 10.25100/cm.v54i3.5353. eCollection 2023 Jul-Sep.
4
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.原发性血小板增多症：2024 年诊断、风险分层和治疗更新。
Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25.
5
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.聚乙二醇干扰素 α-2a 可使晚期原发性血小板增多症和红细胞增多症患者获得较高的血液学和分子学缓解率。
J Clin Oncol. 2009 Nov 10;27(32):5418-24. doi: 10.1200/JCO.2009.23.6075. Epub 2009 Oct 13.
6
Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia.Janus激酶2、钙网蛋白或骨髓增殖性白血病病毒癌基因突变型原发性血小板增多症与三阴性原发性血小板增多症的临床和血液学参数比较
Cureus. 2022 Mar 15;14(3):e23171. doi: 10.7759/cureus.23171. eCollection 2022 Mar.
7
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.四种不同亚型骨髓增殖性肿瘤患者（原发性骨髓纤维化、原发性血小板增多症、真性红细胞增多症和无法分类的骨髓增殖性肿瘤）的CALR、JAK2和MPL突变谱
Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM.
8
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.JAK2 或 CALR 突变状态定义了具有显著不同临床过程和结局的特发性血小板增多症亚型。
Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.
9
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症：2021 年诊断、风险分层和治疗更新。
Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23.
10
Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.聚乙二醇化干扰素α-2a在非临床试验治疗的骨髓增殖性肿瘤患者中临床有效且耐受性良好。
Leuk Res. 2017 Mar;54:73-77. doi: 10.1016/j.leukres.2017.01.006. Epub 2017 Jan 5.
引用本文的文献
1
Contraception in Myeloproliferative Neoplasms: A Pharmacological Review.骨髓增殖性肿瘤中的避孕：药理学综述
Eur J Haematol. 2025 Oct;115(4):344-348. doi: 10.1111/ejh.70014. Epub 2025 Jul 28.
2
Molecular Mechanisms Determining Mammalian Oocyte Quality with the Treatment of Cancer Therapy.决定哺乳动物卵母细胞质量的分子机制及其在癌症治疗中的处理。
Adv Anat Embryol Cell Biol. 2024;238:97-119. doi: 10.1007/978-3-031-55163-5_5.
3
Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review.酪氨酸激酶抑制剂时代慢性髓性白血病妊娠结局及文献综述
Hematol Rep. 2022 Mar 20;14(1):45-53. doi: 10.3390/hematolrep14010008.
本文引用的文献
1
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia.妊娠结局、风险因素和妊娠原发性血小板增多症患者的细胞计数趋势。
Leuk Res. 2020 Nov;98:106459. doi: 10.1016/j.leukres.2020.106459. Epub 2020 Sep 29.
2
Clinical Exome Sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: A pilot study in patients from the state of Qatar.临床外显子组测序揭示骨髓增殖性肿瘤中的新致病突变：来自卡塔尔的患者的一项试点研究。
Gene. 2019 Mar 20;689:34-42. doi: 10.1016/j.gene.2018.12.009. Epub 2018 Dec 13.
3
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.聚乙二醇化干扰素α-2a用于妊娠期原发性血小板增多症：结局与安全性。病例系列报道
Haematologica. 2016 May;101(5):e182-4. doi: 10.3324/haematol.2015.139691. Epub 2016 Jan 27.
4
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.CALR 突变的原发性血小板增多症患者对干扰素-α治疗的临床和分子反应。
Blood. 2015 Dec 10;126(24):2585-91. doi: 10.1182/blood-2015-07-659060. Epub 2015 Oct 20.
5
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.聚乙二醇干扰素 α-2a 在国际 118 例进展期骨髓增殖性肿瘤患者中的应用经验。
Haematologica. 2012 Oct;97(10):1570-3. doi: 10.3324/haematol.2011.061390. Epub 2012 Mar 14.
6
The renaissance of interferon therapy for the treatment of myeloid malignancies.干扰素治疗髓系恶性肿瘤的复兴。
Blood. 2011 May 5;117(18):4706-15. doi: 10.1182/blood-2010-08-258772. Epub 2011 Mar 9.
7
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.聚乙二醇干扰素 α-2a 可使晚期原发性血小板增多症和红细胞增多症患者获得较高的血液学和分子学缓解率。
J Clin Oncol. 2009 Nov 10;27(32):5418-24. doi: 10.1200/JCO.2009.23.6075. Epub 2009 Oct 13.
8
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.α干扰素治疗bcr-abl阴性骨髓增殖性肿瘤
Leukemia. 2008 Nov;22(11):1990-8. doi: 10.1038/leu.2008.280. Epub 2008 Oct 9.
9
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.聚乙二醇化干扰素-α-2a在真性红细胞增多症中可诱导完全血液学和分子反应，且毒性较低。
Blood. 2008 Oct 15;112(8):3065-72. doi: 10.1182/blood-2008-03-143537. Epub 2008 Jul 23.
10
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.聚乙二醇化干扰素α-2b治疗真性红细胞增多症和原发性血小板增多症的II期试验：可行性、临床和生物学效应以及对生活质量的影响。
Cancer. 2006 Jun 1;106(11):2397-405. doi: 10.1002/cncr.21900.
Zotero 插件